60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
종목 코드 SXTP
회사 이름60 Degrees Pharmaceuticals Inc
상장일Jul 12, 2023
CEODr. Ll S. Dow, Ph.D.
직원 수3
유형Ordinary Share
회계 연도 종료Jul 12
주소1025 Connecticut Avenue Nw
도시WASHINGTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호20036
전화12023275422
웹사이트https://60degreespharma.com/
종목 코드 SXTP
상장일Jul 12, 2023
CEODr. Ll S. Dow, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음